Stock Research: Dr. Reddy's

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Dr. Reddy's

NSI:DRREDDY INE089A01023
67
  • Value
    68
  • Growth
    63
  • Safety
    Safety
    50
  • Combined
    70
  • Sentiment
    48
  • 360° View
    360° View
    67
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. It operates in the pharmaceutical industry, specializing in APIs, generics, branded generics, biosimilars, and OTC pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. In the last fiscal year, the company had a market cap of $12,191 million, profits of $2,558 million, and revenue of $3,820 million, with 26944 employees.

more

ANALYSIS: With an Obermatt 360° View of 67 (better than 67% compared with alternatives), overall professional sentiment and financial characteristics for the stock Dr. Reddy's are above average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators above average for Dr. Reddy's. The consolidated Value Rank has an attractive rank of 68, which means that the share price of Dr. Reddy's is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 68% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 63, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. The company is also safely financed with a Safety Rank of 50. But the professional market sentiment is below average compared with other stock investment alternatives with a Sentiment Rank of only 48. Professional investors are more confident in 52% other stocks. ...read more

more
Index
CNX Nifty 50
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 23-Jun-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
68 65 63 61
Growth
63 13 31 47
Safety
Safety
50 51 59 47
Sentiment
48 43 84 50
360° View
360° View
67 25 76 47
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
20 21 38 83
Opinions Change
50 10 39 50
Pro Holdings
n/a 54 99 8
Market Pulse
39 88 77 57
Sentiment
48 43 84 50
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
68 65 63 61
Growth
63 13 31 47
Safety Safety
50 51 59 47
Combined
70 21 53 51
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
49 56 62 61
Price vs. Earnings (P/E)
56 75 82 63
Price vs. Book (P/B)
62 57 62 58
Dividend Yield
51 42 37 42
Value
68 65 63 61
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
21 48 17 46
Profit Growth
86 25 51 86
Capital Growth
66 1 46 42
Stock Returns
43 43 67 21
Growth
63 13 31 47
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
51 56 60 44
Refinancing
70 72 74 66
Liquidity
44 46 52 47
Safety Safety
50 51 59 47

Similar Stocks

Discover high‑ranked alternatives to Dr. Reddy's and broaden your portfolio horizons.

AIA Engineering

NSI:AIAENG
Country: India
Industry: Industrial Machinery
Size: Medium
Full Stock Analysis

Gujarat Gas

NSI:GUJGASLTD
Country: India
Industry: Gas Utilities
Size: Large
Full Stock Analysis

Aurobindo Pharma

NSI:AUROPHARMA
Country: India
Industry: Pharmaceuticals
Size: X-Large
Full Stock Analysis

Cipla

NSI:CIPLA
Country: India
Industry: Pharmaceuticals
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

This stock has excellent financial qualities (value, growth, and safety are high) but a negative professional market sentiment. It suits an investor who believes the negative sentiment is a temporary overreaction and is looking for a financially solid company.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: